All In Biotech

NDA 050790 · Abbvie

Restasis Multidose

Cyclosporine · Ophthalmic · Calcineurin Inhibitor Immunosuppressant

Priority review

Last checked: Nov 19, 2026Latest source record: Aug 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Dec 23, 2002

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,166

250 Phase 3, 65 recruiting

FAERS reports

91,100

60,662 serious, 11,654 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 21, 2025.

RESTASIS MULTIDOSE ® ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs. RESTASIS MULTIDOSE is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs. ( 1 )

Mechanism: Cyclosporine is an immunosuppressive agent when administered systemically. In patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, cyclosporine emulsion is thought to act as a partial immunomodulator. The exact mechanism of action is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 23, 2002 Original approval · Type 3 - New Dosage Form · priority review ReviewLabelLetter
2 products under this application
  • RESTASIS MULTIDOSE · CYCLOSPORINE 0.05% · EMULSION, OPHTHALMIC · Prescription
  • RESTASIS · CYCLOSPORINE 0.05% · EMULSION, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclosporine" as an intervention, any sponsor and status, largest first.

All 1,166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective11,507
  • off label use9,378
  • eye irritation6,681
  • product use in unapproved indication3,873
  • eye pain3,413
  • nausea3,174
  • headache3,156
  • diarrhoea3,140
  • pyrexia3,112
  • fatigue3,078
  • vision blurred2,697
  • pain2,657

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004908
2005937
20061,072
20071,048
20081,793
20092,070
20102,639
20113,374
20122,715
20131,991
20142,616
20153,248
20164,300
20174,465
20184,346
20195,384
20205,813
20215,698
20227,320
20237,509
20248,330
20257,700
20265,818

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Restasis (Cyclosporine)

2024 spending

$1.29B

Beneficiaries

472,657

1,360,998 claims

Per beneficiary

$2,729

$10.20 per unit

View as table
YearSpending
2020$1,451,534,384
2021$1,628,418,856
2022$1,646,136,457
2023$1,501,664,198
2024$1,289,753,142

Part D: Restasis Multidose (Cyclosporine)

2024 spending

$64.2M

Beneficiaries

26,035

79,985 claims

Per beneficiary

$2,466

$111.94 per unit

View as table
YearSpending
2020$55,824,261
2021$67,251,885
2022$76,685,454
2023$67,714,085
2024$64,201,709

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,031 on PubMed

Sponsor: AbbVie · Also marketed as Restasis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.